Influence of Timing of Implant Placement on Early Healing Molecular Events
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age25+
SponsorQueen Mary University of London
About this trial
Dental implants have been on the market for several years and they are routinely used to replace single/multiple missing teeth with a high success rate. However, there is still a limited number of studies comparing the influence of timing of implant placement on wound healing. In addition, there is no data available on the signaling pathways and the expression of healing biomarkers involved in the early stages of osseointegration after immediate implant placement (IP) or delayed implant placement (DP).
The primary objective of this study is to describe changes in the expression of inflammatory, angiogenesis and osseous biomarkers of saliva at 1, 3, 7, 15 and 30 days and of PICF at 3, 7, 15 and 30 days after immediate implant placement (IP) compared with delayed placement (DP).
Eligibility criteria
Qualifiers
Age ≥25 years old
Good/controlled medical and psychological health
Good oral hygiene (FMPS≤20%)
Presence of a tooth in the aesthetic region (from incisor to second premolar) in need of extraction and further oral rehabilitation with a single dental implant.
Disqualifiers
Any known systemic disease severely affecting bone metabolism (e.g., Cushing's syndrome, Crohn's disease, rheumatoid arthritis, osteoporosis or diabetes type I and uncontrolled diabetes type II).
Self-reported HIV or viral hepatitis.
Self-reported alcoholism or chronic drug abuse.
Smokers (including current smokers or former smokers who had quit for < 3 months); patients reporting use of vape/e-cigarettes will also be excluded.
Trial design
Treatments tested in this trial
- Immediate implant placement and guided bone regeneration (Test)
- Late implant placement and guided bone regeneration (Control)
Treatment groups
24 Participants
are divided into 2 treatment groupsSponsors and collaborators
Queen Mary University of London
Lead sponsor
University of Belgrade
Collaborator
Source ClinicalTrials.gov